# Study of CP-675,206 in Refractory Melanoma

> **NCT00254579** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 251 (actual)

## Conditions studied

- Refractory Melanoma

## Interventions

- **DRUG:** CP-675,206

## Key facts

- **NCT ID:** NCT00254579
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254579, "Study of CP-675,206 in Refractory Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00254579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*